The Changing Environment of Academic/Industry Relationships December 1, 2018
Agenda Part I – AMC Innovations and Commercialization Models a) Key Industry Trends – AMC’s, Industry b) Models of Collaboration between AMC’s and the Industry i. Incubator / Accelerators c) Industry Alliances and Partnerships – Examples / Case Studies d) Philanthropy – Social Impact of Investing Part II – Strategic Focus – Risk s and Benefits – Case Studies a) Translational Genomics b) Tool’s and Technology c) Women’s Health d) Data Science Program – Diabetes Data Science Part III – Geographic Region / Precincts – Advances Shared Services Models a) “ What if you could build a regional research infrastructure with out misaligned incentives?” PwC 2
Part I - AMC Innovation and Commercialization Models A. Industry Trends – AMC’s Pharm R&D, Data Driven Initiatives PwC
Traditional academic medical center research models are unsustainable in a time of fiscal uncertainty Margin Uncertainty Federal Research Technology Driven by Funding at Risk Disruption Value-based Care Changes In Reductions in Regulatory Clinical Philanthropy Uncertainty Reimbursement Additional models of research development must be explored to remain competitive in the evolving academic research landscape Sources: http://www.nsf.gov/news/news_summ.jsp?cntn_id=130156, http://fas.org/sgp/crs/misc/R43341.pdf, http://www.beckershospitalreview.com/strategic-planning/is-academic-medicine-as-we-know-it-doa.html, http://chronicle.com/article/Donations-Rose- Only-Slightly/139879/ PwC 4
Research funding organizations provide us an “insider’s” perspective on the key issues Opportunities Challenges Open Data, Open Science A Technological Wall? “Support for oncology research has faced challenges primarily due to “Data science is driving the next wave of disruption” technological advances that require a highly specialized infrastructure.” Keen to see their research support generate compounding returns, funders are particularly • Lack of facilities, equipment, skilled technicians, data resources, etc. have interested in promoting a culture of data sharing across investigators, and training lessened funders’ ability to advance on -site innovative research protocols on researchers to use “big data”. oncology issues • Tools, platforms, and expertise exist that can derive additional value from disparate data • Has also led to difficulties in recruiting physician-scientists able to advance relevant to oncology science these research areas • Federal open data initiatives – under-utilized resources to advance basic/applied science • Open science can enhance ‘traditional’ science (e.g. clinical trials) with patient engagement Collaborate on Shared Priorities Choosing to Focus “PMI, health equity, and translational science are priorities” “ What will we give up to pursue the priorities?” Public-private partnerships and joining forces with patient advocacy groups also offer potential Funders are deliberating which opportunities might have the largest impacts appeal to help increase funding impact. and how they should proportion resources across the research value chain. • External partners can help identify gaps in science-to-practice • Which diseases/conditions/public health issues deserve the most focus? • Emerging opportunities for joint funding, strategic partnership, & initiative co-promotion • Which recent discoveries might be ripe for translational research? Addressing the Patient/Community Voice Remaining Flexible “Patient engagement is the key to revitalizing research” “ How do we respond rapidly to emerging public health needs?” External partners are at the forefront of new models for community engagement. Emerging discoveries, public health needs and as-yet unknown future research trends drive the increasing value that funders place on flexibility. • Digital as a catalyst for expanding funders’ voices for health equity and social determinants • Flexibility is a capability funders seek to develop for themselves and look for in • Patient-centered organizations can help facilitate linkages to important/under-resourced the research community communities and constituents 5 PwC
Systemic healthcare trends are positioning health organizations to take advantage of data-driven initiatives PwC 6
Scientific and technological advances, such as genomic medicine, are driving a deluge of new data and opportunities for academic institutions A transformation in healthcare is underway • Increased accountability and value-based approaches • Treatment driven by the molecular underpinnings, rather than the resulting symptoms Genomic medicine is at it’s tipping point • The $1000 genome is now a reality • Total human genomes sequenced increased from < 20 to >10K in the past 5 years Genomic medicine is a data-driven science • Sequencing a single human genome can produce up to a terabyte of data • Robust analyses can involve hundreds or thousands of genomes PwC 7
There is a fundamental need to collaborate and share data across organizations to realize unparalleled value There is an …but there is a lack of …and organizations unprecedented amount sophisticated solutions are hoarding data and of data being generated to transform how data working in silos by an increasing is being leveraged and because of a lack of number of sources… shared… trusted solutions “We believe the next step must be to transition to a system 93% of executives believe 90% whereby a body unconnected their organizations are with the generation of data acts as losing revenue (14% the custodian of access to the annually) as a result of not data … [to make it] available from multiple companies, public-sector leveraging information organizations, and funders.” collected 2 of the world’s data has been Analysis created in the last 2 years - Perry Nisen, SVP of Science and Innovation, GSK alone 1 PwC 8 Sources: 1) IBM, Big Data, 2013 ; 2) Oracle; From Overload to Impact: An Industry Scorecard on Big Data Business Challenges
An Explosion of Therapeutic Options Ipilimumab (Yervoy) Lapatinib (Tykerb) Ado-trastuzumab emtansine Nilotinib (Tasigna) (Kadcyla) Obinutuzumab (Gazyva) Afatinib (Gilotrif) Ofatumumab (Arzerra, HuMax-CD20) Melanoma Aldesleukin (Proleukin) Panitumumab (Vectibix) Alemtuzumab (Campath) Pazopanib (Votrient) Axitinib (Inlyta) Pembrolizumab (Keytruda) Belimumab (Benlysta) Pertuzumab (Perjeta) Belinostat (Beleodaq) Ponatinib (Iclusig) Bevacizumab (Avastin) Ramucirumab (Cyramza) Bortezomib (Velcade) Kidney Cancer Regorafenib (Stivarga) Bosutinib (Bosulif) Rituximab (Rituxan, Mabthera) Brentuximab vedotin Romidepsin (Istodax) (Adcetris) Ruxolitinib (Jakafi) Cabozantinib (Cometriq) Siltuximab (Sylvant) Canakinumab (Ilaris) Sipuleucel-T (Provenge) Carfilzomib (Kyprolis) Sorafenib (Nexavar) Ceritinib (Zykadia) Temsirolimus (Torisel) Cetuximab (Erbitux) Tocilizumab (Actemra) Crizotinib (Xalkori) Tofacitinib (Xeljanz) Dabrafenib (Tafinlar) Tositumomab (Bexxar) Dasatinib (Sprycel) Trametinib (Mekinist) Denosumab (Xgeva) Trastuzumab (Herceptin) Erlotinib (Tarceva) Vandetanib (Caprelsa) Everolimus (Afinitor) Vemurafenib (Zelboraf) Gefitinib (Iressa) Vismodegib (Erivedge) Ibritumomab tiuxetan Vorinostat (Zolinza) (Zevalin) Ziv-aflibercept (Zaltrap) Ibrutinib (Imbruvica) Idelalisib (Zydelig) Imatinib (Gleevec ) PwC 9
An Explosion of Therapeutic Options Ado-trastuzumab emtansine (Kadcyla) Ipilimumab (Yervoy) Afatinib (Gilotrif) Lapatinib (Tykerb) Brain Cancer Aldesleukin (Proleukin) Nilotinib (Tasigna) Alemtuzumab (Campath) Head and Neck Cancer Obinutuzumab (Gazyva) Thyroid Cancer Axitinib (Inlyta) Ofatumumab (Arzerra, HuMax-CD20) Melanoma Belimumab (Benlysta) Panitumumab (Vectibix) Lung Cancer Belinostat (Beleodaq) Pazopanib (Votrient) Bevacizumab (Avastin) Myeloma Pembrolizumab (Keytruda) Breast Cancer Bortezomib (Velcade) Pertuzumab (Perjeta) Soft Tissue Sarcoma Bosutinib (Bosulif) Ponatinib (Iclusig) Brentuximab vedotin (Adcetris) Ramucirumab (Cyramza) Gastric Cancer Cabozantinib (Cometriq) Kidney Cancer Regorafenib (Stivarga) Canakinumab (Ilaris) Pancreatic Cancer Rituximab (Rituxan, Mabthera) Colorectal Cancer Carfilzomib (Kyprolis) Romidepsin (Istodax) Prostate Cancer Ceritinib (Zykadia) Ruxolitinib (Jakafi) Cetuximab (Erbitux) Siltuximab (Sylvant) Crizotinib (Xalkori) Sipuleucel-T (Provenge) Leukemia Dabrafenib (Tafinlar) • Multiple targets per therapy Sorafenib (Nexavar) Dasatinib (Sprycel) Temsirolimus (Torisel) • Multiple therapies per target Denosumab (Xgeva) Tocilizumab (Actemra) Erlotinib (Tarceva) Tofacitinib (Xeljanz) Everolimus (Afinitor) Tositumomab (Bexxar) Bone Cancer Gefitinib (Iressa) Trametinib (Mekinist) Lymphoma Ibritumomab tiuxetan (Zevalin) Trastuzumab (Herceptin) Ibrutinib (Imbruvica) Vandetanib (Caprelsa) Idelalisib (Zydelig) Vemurafenib (Zelboraf) Imatinib (Gleevec ) Vismodegib (Erivedge) Vorinostat (Zolinza) Ziv-aflibercept (Zaltrap ) 2000 2005 2010 2015 PwC 10
A Rapidly Shifting Landscape 1,600,000 3500 150,000 Oncology 1,400,000 Documented Clinical 3000 1,200,000 Publications Mutations Trials 2500 100,000 1,000,000 2000 800,000 1500 600,000 50,000 1000 400,000 200,000 500 0 0 0 1920 1960 2000 2/22/08 11/18/10 8/14/13 1954 1974 1994 2014 PwC 11
3,140 Pages of Guidelines PwC 12
Recommend
More recommend
